Gestational trophoblastic neoplasia other diagnostic studies

	Gestational trophoblastic neoplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gestational trophoblastic neoplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gestational trophoblastic neoplasia other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gestational trophoblastic neoplasia other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gestational trophoblastic neoplasia other diagnostic studies
CDC on Gestational trophoblastic neoplasia other diagnostic studies
Gestational trophoblastic neoplasia other diagnostic studies in the news
Blogs on Gestational trophoblastic neoplasia other diagnostic studies
Directions to Hospitals Treating Gestational trophoblastic neoplasia
Risk calculators and risk factors for Gestational trophoblastic neoplasia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

2-[F-18]fluoro-2-deoxy-D-glucose (FDG)-PET scanning may be used to study the extent of malignancy in gestational trophoblastic neoplasia.^[1]^[2]
It may be useful in cases of occult disease of the lung parenchyma, pulmonary artery, liver and broad ligament when ultrasound, CT, MRI imaging results are equivocal.^[3]

↑ Sironi, S; Picchio, M; Mangili, G; Garavaglia, E; Zangheri, B; Messa, C; Voci, C; Taccagni, G.L; Maschio, A.Del; Fazio, F (2003). "[18f]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients". Gynecologic Oncology. 91 (1): 226–230. doi:10.1016/S0090-8258(03)00437-2. ISSN 0090-8258.
↑ Hebart, H.; Erley, C.; Kaskas, B.; Mayer, R.; Konig, M.; Einsele, H.; Bokemeyer, C.; Meerpohl, H. G.; Feine, U.; Kanz, L. (1996). "Positron emission tomography helps to diagnose tumor emboli and residual disease in chonocarcinoma". Annals of Oncology. 7 (4): 416–418. doi:10.1093/oxfordjournals.annonc.a010611. ISSN 0923-7534.
↑ Numnum, T. Michael; Leath, Charles A.; Straughn, J. Michael; Conner, Michael G.; Barnes, Mack N. (2005). "Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy". Gynecologic Oncology. 97 (2): 713–715. doi:10.1016/j.ygyno.2005.01.049. ISSN 0090-8258.